Skip to main content

Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies.

Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, Tewari M

Publication: Cancer Prev Res (Phila) (2012) • Vol 5 • Page 492-7PMID: 22158052View on PubMed

Purpose

The purpose of this paper was to determine if plasma levels of circulating microRNAs (miRNAs) reported in the literature to be tumor biomarkers are reflective of blood cell counts.

Conclusion

46 of the 79 miRNA species previously reported in the literature to be solid tumor biomarkers were highly expressed in at least one blood cell type from a healthy individual. Plasma miRNA expression reflected the blood cell composition of the sample, as plasma levels of miRNA species that exhibited a high level of expression in lymphoid or myeloid cells were correlated with lymphoid and myloid cell counts, respectively, in 43 K2EDTA plasma specimens. Further, levels of miRNA highly expressed in red blood cells were enriched 20-30 fold in plasma when the specimen was hemolyzed. Plasma levels of miRNAs highly expressed in myeloid cells and lymphoid cells shadowed changes in myeloid cell and lymphoid cell counts, respectively, in a patient undergoing myloablative chemotherapy and hematopoetic stem cell transplant.

Studies (1)

Purpose

The purpose of this study was to determine if plasma levels of circulating miRNAs reported in the literature to be tumor biomarkers are reflective of blood cell counts. Blood from a single healthy patient was separated into cellular components and K2EDTA plasma. K2EDTA plasma and complete blood count results were obtained from 42 consecutive patients with a wide range of diagnoses. Further plasma specimens were obtained from a single patient over the course of myloablative chemotherapy. miRNA was isolated on the day of plasma collection and was quantified using individual and array real-time qRT-PCR.

Summary of Findings

46 of the 79 miRNA species previously reported in the literature to be solid tumor biomarkers were highly expressed in at least one blood cell type from a healthy individual. The plasma miRNA expression profile was reflective of the blood cell population, as 42 of the 46 miRNAs that were highly expressed in blood cells were also highly expressed in plasma. Specifically, plasma levels of 4 miRNAs (which were highly expressed in myeloid cells) were  correlated  with myeloid cell counts in 42 K2EDTA plasma specimens. Plasma levels of an additional miRNA that was highly expressed in lymphoid cells was modestly correlated (r=0.67) with lymphocyte counts, but plasma levels of a liver-specific miRNA were not correlated with any blood cell count. Similarly, levels of 4 miRNA highly expressed in red blood cells were enriched 20-30 fold in plasma when the specimen was hemolyzed, but similar changes in levels of non-red blood cell miRNA were not found after hemolysis. Plasma levels of miRNAs highly expressed in myeloid cells and lymphoid cells mirrored changes in myeloid cell and lymphoid cell counts, respectively, in a patient undergoing myloablative chemotherapy and hematopoetic stem cell transplant.

 

  • Biospecimens

    FluidBlood
    FluidPlasma
  • Preservation Types

    None (Fresh)
  • Diagnoses

    Normal
    NeoplasticLymphoma
    NeoplasticCarcinoma
    NeoplasticLeukemia
    NeoplasticOther
    Cardiovascular Disease
    Other diagnoses
  • Platforms

    RNALow density array
    RNAReal-time qRT-PCR
    Cell count/volumeFlow cytometry
    Cell count/volumeHematology/ auto analyzer
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionBiomarker level
    A range of complete blood counts
    Biospecimen AcquisitionTime of biospecimen collection
    1 day post-infusion
    1 days pre-infusion
    11 days post-infusion
    13 days post-infusion
    15 days post-infusion
    27 days post-infusion
    3 day post-infusion
    3 days pre-infusion
    4 days pre-infusion
    5 days post-infusion
    5 days pre-infusion
    7 days post-infusion
    9 days post-infusion
    Infusion of hematopoetic stem cell
    Biospecimen Aliquots and ComponentsBlood and blood products
    Plasma
    Whole blood
    Biospecimen Aliquots and ComponentsHemolysis
    Absent
    Present